A key result of the exploratory biomarker was the first-defined classification of a TME phenotype to stratify all MPR patients in response to neoadjuvant PD-L1 blockade, as well as patients with longer OS in the TCGA ESCC and nine pan-cancer immunotherapy cohorts. The gene discussed is CD274; the disease is cancer.